N-SIDE, provider of innovative software and strategic consulting services, announced that AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials. Within the scope of this agreement, AstraZeneca will use specifically the N-SIDE Supply and...
MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications,...
Veeva SiteVault Free allows sites to manage regulatory documentation and study information for all trials Veeva aims to help industry accelerate clinical research and streamline study start-up and execution across sites and sponsors PLEASANTON, Calif.–(BUSINESS...
An early phase study was conducted in the U.S. in which different combinations of DNA (DNA-HIV-PT123) and protein (AIDSVAX® B/E) vaccines were administered in four randomized treatment groups (T1, T2, T3, T4), to determine which strategy would induce favorable...
MARLTON, N.J. & LONG BEACH, Calif.–(BUSINESS WIRE)–CNS Network (“CNS”) and Hassman Research Institute (“HRI”) have completed a strategic merger to form Apex Innovative Sciences, Inc. (“Apex” or the “Company”). The combination represents the...
– Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC – Onvansertib preclinical data provides rationale for clinical trial targeting the 80% of TNBC that harbors the p53...
Email
Text